Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease What is the Best Way to Assess the Safety Profile of a Drug?

(E-pub Ahead of Print)

Author(s): Clara Yzet, Stacy S. Tse, Maia Kayal, Robert Hirten, Jean-Frédéric Colombel*.

Journal Name: Current Pharmaceutical Design

Become EABM
Become Reviewer

Abstract:

The emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the post-marketing period. In this article, we review how to best assess the safety parameters of new IBD medications, from the earliest stage of development to population-based registries, with a focus on the special populations often excluded from the evaluation process.

Keywords: Drug development, safety, adverse effect, side effect, biologics, inflammatory bowel disease, clinical trials

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1381612825666190308102021
Price: $95

Article Metrics

PDF: 1